Adobe Spark copy 1024x536 - Oxford BioMedica on the Verge of a Cure?

Oxford BioMedica on the Verge of a Cure?

In our weekly look into the world of business, Luke Pritchard from our Corporate...

Back to News and Events

Oxford BioMedica on the Verge of a Cure?

3rd July 2017

News : Commercial

In our weekly look into the world of business, Luke Pritchard from our Corporate and Commercial team, takes a look at Oxford Biomedica’s recent medical breakthrough…

Oxford Biomedica was created in 1995 as a spin out from Oxford University, specialising in the development and commercialisation of gene-based medicines.  There are rumours that it could now be on the brink of its most significant breakthrough.

Shares in the company rose by almost 40% last week, amid growing expectations that it is set to announce a revolutionary new treatment for leukaemia.

Analysts have estimated that the new drug could generate annual revenues in excess of $1bn.

It is some ten days since the anniversary of the death of Jonas Salk.  Salk discovered and developed one of the first vaccines for polio.  In the interests of ensuring access to the vaccine, Salk chose not to patent it – a decision said to have cost him $7 billion.

As Oxford Biomedica and its shareholders stand on the brink of a breakthrough, Jonas Salk reminds us that they face a moral maze on the pathway to profits.

Sign up to our eMagazine

@POOLEALCOCK

Issue 4 of Poole Alcock Insight is here! Grab a coffee and enjoy Augusts edition of our free Emagazine. https://t.co/qOHgJ9313q

Posted 18th August 2020

@POOLEALCOCK

Weve had a 5* review from Ian: Kate Heath and team - once again, amazing https://t.co/QNvMmTlgu2

Posted 29th July 2020

call cloudicon_laptop_add icon_purchase_new icon_purchase_standard icon_quill icon_remortgage icon_sale_purchase icon_sale icon_tick search skull speedo tail-right (1)Created with Sketch. tail_right tick_circle_green tick_circle